UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,396	11/02/2006	Ping Li	021238-832	1054
	7590 08/04/201 INGERSOLL & ROOI	EXAMINER		
POST OFFICE	BOX 1404	NGUYEN, PHU HOANG		
ALEXANDRIA, VA 22313-1404			ART UNIT	PAPER NUMBER
		1791		
			NOTIFICATION DATE	DELIVERY MODE
			08/04/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ADIPFDD@bipc.com offserv@bipc.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/560,396	LI ET AL.	
Examiner	Art Unit	

	PHU H. NGUYEN	1791	
The MAILING DATE of this communication appear	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>19 July 2010</u> FAILS TO PLACE THIS APPL	ICATION IN CONDITION FOR AL	LOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit al (with appeal fee) in compliance v	, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date of this Action no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)	dvisory Action, or (2) the date set forth i tter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extender 37 CFR 1.17(a) is calculated from: (1) the expiration date of the slate forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Offic	te extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exten Notice of Appeal has been filed, any reply must be filed with AMENDMENTS	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, b (a) They raise new issues that would require further con (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or (d) They present additional claims without canceling a c	nsideration and/or search (see NOT w); er form for appeal by materially rec	E below); lucing or simplifying th	
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowed an endowable claim(s).	 owable if submitted in a separate, t	imely filed amendmer	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,2,10,17 and 21. Claim(s) withdrawn from consideration: 31,32,35,37,39,40. AFFIDAVIT OR OTHER EVIDENCE	ided below or appended.	be entered and an ex	кріапаціон от
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to over showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fails	to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•	
11. The request for reconsideration has been considered but See Continuation Sheet.		condition for allowand	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s). (l13. ☐ Other:	P10/SB/08) Paper No(s)		
/Philip C Tucker/ Supervisory Patent Examiner, Art Unit 1791			

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments filed 7/19/2010 have been fully considered but they are not persuasive.

Applicant essentially argues that claim 1 is not anticipated by Snaidr because Snaidr fails to show that the patterned deposit includes regions of the cigarette wrapper that are left unprinted and available to facilitate diffusion of CO through the wrapper as described in the specification (paragraph 40). However, it is noted that the featutres upon which the Applicant relies (i.e., the patterned deposit includes regions of the cigarette wrapper that are left unprinted and available to facilitate diffusion of CO through the wrapper) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Therefore, Claim is anticipated by Snaidr.

The Examiner believes that the Applicant further argues that claims 2 and 17 depend from claim 1 and therefore not anticipated by Snaidr. However, as discussed above, claim 1 is anticipated by Snaidr.

The Examiner believes that the Applicant also argues that claims 10 and 21 depend from claim 1 and the secondary reference of Smith fails to remedy the alledged deficiencies of Snaidr. However, as explained above, claim 1 is anticipated by Snaidr therefore Snaidr does not have any deficiency.